[Form 4] Cardinal Health, Inc. Insider Trading Activity
Deborah Weitzman, an officer listed as "CEO, PSS Segment" at Cardinal Health (CAH), was recorded as acquiring 39,100 performance share units on 08/12/2025 that are scheduled to settle on August 15, 2025.
The award is reported at a $0 price and is described as performance share units that will settle to common shares on the stated settlement date. After the reported acquisition, Ms. Weitzman鈥檚 beneficial ownership is shown as 88,229 common shares held directly. The filing shows this transaction as an acquisition (code A) and Table II reports no derivative securities.
Deborah Weitzman, indicata come "CEO, PSS Segment" presso Cardinal Health (CAH), risulta aver acquisito 39,100 unit脿 azionarie legate alle performance in data 08/12/2025, con regolamento previsto per il 15 agosto 2025.
L'assegnazione 猫 riportata a un prezzo di $0 ed 猫 descritta come unit脿 azionarie legate alle performance che verranno convertite in azioni ordinarie alla data di regolamento indicata. Dopo l'acquisizione segnalata, la titolarit脿 effettiva della sig.ra Weitzman risulta pari a 88,229 azioni ordinarie detenute direttamente. La documentazione presentata indica questa operazione come un'acquisizione (codice A) e la Tabella II non riporta strumenti derivati.
Deborah Weitzman, registrada como "CEO, PSS Segment" en Cardinal Health (CAH), aparece como adquirente de 39,100 unidades de acciones por desempe帽o el 08/12/2025, con liquidaci贸n prevista para el 15 de agosto de 2025.
El otorgamiento se declara a un precio de $0 y se describe como unidades de acciones por desempe帽o que se convertir谩n en acciones ordinarias en la fecha de liquidaci贸n indicada. Tras la adquisici贸n comunicada, la titularidad beneficiaria de la Sra. Weitzman figura en 88,229 acciones ordinarias en propiedad directa. La presentaci贸n muestra esta transacci贸n como una adquisici贸n (c贸digo A) y la Tabla II no informa sobre valores derivados.
Cardinal Health(CAH)鞐愳劀 "CEO, PSS Segment"搿� 旮办灛霅� Deborah Weitzman鞚� 08/12/2025鞐� 39,100臧滌潣 靹标臣 欤检嫕 雼渼(performance share units)毳� 旆摑頃� 瓴冹溂搿� 旮半霅橃棃鞙茧┌, 頃措嫻 雼渼電� 2025雲� 8鞗� 15鞚检棎 鞝曥偘霅� 鞓堨爼鞛呺媹雼�.
頃措嫻 靾橃棳電� 臧�瓴� $0搿� 鞁犼碃霅橃棃瓿�, 氇呾嫓霅� 鞝曥偘鞚检棎 氤错喌欤茧 鞝曥偘霅橂姅 靹标臣 欤检嫕 雼渼搿� 靹る獏霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃霅� 旆摑 鞚错泟 Weitzman 鞌潣 鞁れ唽鞙犽姅 歆侅爲 氤挫湢頃� 88,229 氤错喌欤茧 響滌嫓霅╇媹雼�. 頃措嫻 靹滊電� 鞚� 瓯半灅毳� 旆摑(旖旊摐 A)鞙茧 響滌嫓頃橂┌, 響� II鞐愲姅 韺岇儩歃濌秾鞚� 氤搓碃霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Deborah Weitzman, indiqu茅e comme "CEO, PSS Segment" chez Cardinal Health (CAH), est enregistr茅e comme ayant acquis 39,100 unit茅s d'actions de performance le 08/12/2025, dont le r猫glement est pr茅vu le 15 ao没t 2025.
L'attribution est d茅clar茅e 脿 un prix de 0 $ et est d茅crite comme des unit茅s d'actions de performance qui seront converties en actions ordinaires 脿 la date de r猫glement indiqu茅e. Apr猫s l'acquisition signal茅e, la d茅tention b茅n茅ficiaire de Mme Weitzman est indiqu茅e 脿 88,229 actions ordinaires d茅tenues directement. Le d茅p么t qualifie cette op茅ration d'acquisition (code A) et le tableau II ne mentionne aucun titre d茅riv茅.
Deborah Weitzman, aufgef眉hrt als "CEO, PSS Segment" bei Cardinal Health (CAH), wurde als Erwerberin von 39,100 Performance-Share-Einheiten am 08/12/2025 verzeichnet, die am 15. August 2025 abgerechnet werden sollen.
Die Zuteilung wird mit einem Preis von $0 angegeben und als Performance-Share-Einheiten beschrieben, die am angegebenen Abrechnungsdatum in Stammaktien umgewandelt werden. Nach der gemeldeten Erwerbung wird das wirtschaftliche Eigentum von Frau Weitzman mit 88,229 direkt gehaltenen Stammaktien ausgewiesen. Die Meldung f眉hrt diese Transaktion als Erwerb (Code A) und Tabelle II weist keine derivativen Wertpapiere aus.
- None.
- None.
Insights
TL;DR: Routine equity compensation grant of 39,100 PSUs at $0 increases direct holdings to 88,229; materiality unclear without outstanding share count.
The filing documents a standard performance-based equity award recorded as an acquisition (code A) and priced at $0, indicating a grant rather than a market purchase. The units are scheduled to settle on August 15, 2025 and will convert to common shares upon settlement. No derivative securities are listed in Table II. Assessment of materiality requires the companys total outstanding share count and prior insider holdings; those figures are not provided in this form.
TL;DR: Insider award aligns compensation with future performance; disclosure appears routine and compliant but impact is neutral without further context.
The Form 4 shows an officer-level recipient and documents the grant quantity, settlement date, and post-transaction direct ownership. The presence of an attorney-in-fact signature is a procedural detail confirming the reports execution. From a governance perspective, the transaction is a routine executive equity award; whether it meaningfully affects control, dilution, or incentives cannot be determined from this filing alone because outstanding share data and grant terms beyond settlement timing are not included.
Deborah Weitzman, indicata come "CEO, PSS Segment" presso Cardinal Health (CAH), risulta aver acquisito 39,100 unit脿 azionarie legate alle performance in data 08/12/2025, con regolamento previsto per il 15 agosto 2025.
L'assegnazione 猫 riportata a un prezzo di $0 ed 猫 descritta come unit脿 azionarie legate alle performance che verranno convertite in azioni ordinarie alla data di regolamento indicata. Dopo l'acquisizione segnalata, la titolarit脿 effettiva della sig.ra Weitzman risulta pari a 88,229 azioni ordinarie detenute direttamente. La documentazione presentata indica questa operazione come un'acquisizione (codice A) e la Tabella II non riporta strumenti derivati.
Deborah Weitzman, registrada como "CEO, PSS Segment" en Cardinal Health (CAH), aparece como adquirente de 39,100 unidades de acciones por desempe帽o el 08/12/2025, con liquidaci贸n prevista para el 15 de agosto de 2025.
El otorgamiento se declara a un precio de $0 y se describe como unidades de acciones por desempe帽o que se convertir谩n en acciones ordinarias en la fecha de liquidaci贸n indicada. Tras la adquisici贸n comunicada, la titularidad beneficiaria de la Sra. Weitzman figura en 88,229 acciones ordinarias en propiedad directa. La presentaci贸n muestra esta transacci贸n como una adquisici贸n (c贸digo A) y la Tabla II no informa sobre valores derivados.
Cardinal Health(CAH)鞐愳劀 "CEO, PSS Segment"搿� 旮办灛霅� Deborah Weitzman鞚� 08/12/2025鞐� 39,100臧滌潣 靹标臣 欤检嫕 雼渼(performance share units)毳� 旆摑頃� 瓴冹溂搿� 旮半霅橃棃鞙茧┌, 頃措嫻 雼渼電� 2025雲� 8鞗� 15鞚检棎 鞝曥偘霅� 鞓堨爼鞛呺媹雼�.
頃措嫻 靾橃棳電� 臧�瓴� $0搿� 鞁犼碃霅橃棃瓿�, 氇呾嫓霅� 鞝曥偘鞚检棎 氤错喌欤茧 鞝曥偘霅橂姅 靹标臣 欤检嫕 雼渼搿� 靹る獏霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃霅� 旆摑 鞚错泟 Weitzman 鞌潣 鞁れ唽鞙犽姅 歆侅爲 氤挫湢頃� 88,229 氤错喌欤茧 響滌嫓霅╇媹雼�. 頃措嫻 靹滊電� 鞚� 瓯半灅毳� 旆摑(旖旊摐 A)鞙茧 響滌嫓頃橂┌, 響� II鞐愲姅 韺岇儩歃濌秾鞚� 氤搓碃霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Deborah Weitzman, indiqu茅e comme "CEO, PSS Segment" chez Cardinal Health (CAH), est enregistr茅e comme ayant acquis 39,100 unit茅s d'actions de performance le 08/12/2025, dont le r猫glement est pr茅vu le 15 ao没t 2025.
L'attribution est d茅clar茅e 脿 un prix de 0 $ et est d茅crite comme des unit茅s d'actions de performance qui seront converties en actions ordinaires 脿 la date de r猫glement indiqu茅e. Apr猫s l'acquisition signal茅e, la d茅tention b茅n茅ficiaire de Mme Weitzman est indiqu茅e 脿 88,229 actions ordinaires d茅tenues directement. Le d茅p么t qualifie cette op茅ration d'acquisition (code A) et le tableau II ne mentionne aucun titre d茅riv茅.
Deborah Weitzman, aufgef眉hrt als "CEO, PSS Segment" bei Cardinal Health (CAH), wurde als Erwerberin von 39,100 Performance-Share-Einheiten am 08/12/2025 verzeichnet, die am 15. August 2025 abgerechnet werden sollen.
Die Zuteilung wird mit einem Preis von $0 angegeben und als Performance-Share-Einheiten beschrieben, die am angegebenen Abrechnungsdatum in Stammaktien umgewandelt werden. Nach der gemeldeten Erwerbung wird das wirtschaftliche Eigentum von Frau Weitzman mit 88,229 direkt gehaltenen Stammaktien ausgewiesen. Die Meldung f眉hrt diese Transaktion als Erwerb (Code A) und Tabelle II weist keine derivativen Wertpapiere aus.
FAQ
What did Deborah Weitzman acquire in the Form 4 for CAH?
How many Cardinal Health (CAH) shares does Deborah Weitzman beneficially own after the transaction?
What is the price and settlement schedule for the award?
Does the Form 4 report any derivative securities for this reporting person?
What role does Deborah Weitzman hold at Cardinal Health according to the filing?
